Bioventus Inc.
NASDAQ•BVS
CEO: Mr. Mark L. Singleton
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2021-02-11
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Contact Information
Market Cap
$710.20M
P/E (TTM)
24.8
19.6
Dividend Yield
--
52W High
$11.25
52W Low
$5.81
52W Range
Rank48Top 64.4%
3.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q1 2026 Data
Revenue
$132.09M+0.00%
4-Quarter Trend
EPS
$0.05+0.00%
4-Quarter Trend
FCF
$8.36M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Return to Net Income Achieved net income of $27.3M USD in 2025, successfully reversing the $47.0M USD net loss reported previously.
Adjusted EBITDA Improvement Adjusted EBITDA grew to $116.3M USD, marking a $7.4M USD increase over the prior fiscal year results.
Debt Refinancing Completed Secured 2025 Credit Agreement, repaying $332.6M debt, extending maturity profile until July 2030.
Total Net Sales Decline Total net sales $568.1M USD, down 0.9% from $573.3M USD in 2024, driven by Restorative Therapies divestiture.
Risk Factors
Product Revenue Concentration HA products accounted for 49% of 2025 revenue; demand dependence limits growth and profitability outlook.
Credit Agreement Covenants 2025 Credit Agreement imposes leverage and coverage restrictions limiting financial flexibility and future borrowing.
Regulatory Reclassification Risk Potential FDA reclassification of HA products from devices to drugs could necessitate costly clinical studies.
Supply Chain Reliance Top three third-party manufacturers supply 49% of 2025 net sales, posing significant supply chain disruption risk.
Outlook
Core Market Share Growth Strategy centers on strengthening leading positions in core HA, BGS, and Fracture Care product markets.
Emerging Tech Launches Plan full commercial launches for StimTrial and TalisMann PNS technologies in early 2026.
Ultrasonics Platform Expansion Accelerate market penetration for BoneScalpel and expand neXus platform into neurosurgery and general surgery.
International Market Growth Intend to grow international business in current markets and selectively pursue new market opportunities.
Peer Comparison
Revenue (TTM)
$857.50M
$715.90M
$576.30M
Gross Margin (Latest Quarter)
91.5%
79.3%
73.1%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AVNS | $1.16B | -16.6 | -8.9% | 13.2% |
| BFLY | $1.09B | -14.1 | -36.8% | 6.9% |
| BVS | $710.20M | 24.8 | 16.3% | 2.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-3.6%
Flat Growth
4Q Net Income CAGR
-25.3%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 12, 2026
EPS:$0.10
|Revenue:$130.32M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data